Target and tissue selectivity of PROTAC degraders
The DOI matches its Crossref record; 133 of the 133 references it cites were found in a registry or an index.
Abstract
Targeted protein degradation (TPD) strategies have revolutionized how scientists tackle challenging protein targets deemed undruggable with traditional small molecule inhibitors. Many promising campaigns to inhibit proteins have failed due to factors surrounding inhibition selectivity and targeting of compounds to specific tissues and cell types. One of the major improvements that PROTAC (proteolysis targeting chimera) and molecular glue technology can exert is highly selective control of target inhibition. Multiple studies have shown that PROTACs can gain selectivity for their protein targets beyond that of their parent ligands via optimization of linker length and stabilization of ternary complexes. Due to the bifunctional nature of PROTACs, the tissue selective nature of E3 ligases can be exploited to uncover novel targeting mechanisms. In this review, we provide critical analysis of the recent progress towards making selective PROTAC molecules and new PROTAC technologies that will continue to push the boundaries of achieving selectivity. These efforts have wide implications in the future of treating disease as they will broaden the possible targets that can be addressed by small molecules, like undruggable proteins or broadly active targets that would benefit from degradation in specific tissue types.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For instance, PROTAC technology leverages E3 ligases, which may be selectively expressed in certain tissues, to drive the targeted degradation of specific targets,520 offering significant opportunities for AD treatment.”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [520]
Citations
Cites
Highly accurate protein structure prediction with AlphaFold
Jumper, J., Evans, R., Pritzel, A., Green, T., Figurnov, M., Ronneberger, O., Tunyasuvunakool, K., Bates, R., Žídek, A., Potapenko, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03819-2 · Cited by 43,764
A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma
van der Bruggen, P., Traversari, C., Chomez, P., Lurquin, C., De Plaen, E., Van den Eynde, B., Knuth, A., & Boon, T. (1991) · Science · doi:10.1126/science.1840703 · Cited by 3,545
Sakamoto, K. M., Kim, K. B., Kumagai, A., Mercurio, F., Crews, C. M., & Deshaies, R. J. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.141230798 · Cited by 2,609
Comprehensive analysis of kinase inhibitor selectivity
Davis, M. I., Hunt, J. P., Herrgard, S., Ciceri, P., Wodicka, L. M., Pallares, G., Hocker, M., Treiber, D. K., & Zarrinkar, P. P. (2011) · Nature Biotechnology · doi:10.1038/nbt.1990 · Cited by 2,409
Photoremovable Protecting Groups in Chemistry and Biology: Reaction Mechanisms and Efficacy
Klán, P., Šolomek, T., Bochet, C. G., Blanc, A., Givens, R., Rubina, M., Popik, V., Kostikov, A., & Wirz, J. (2013) · Chemical Reviews · doi:10.1021/cr300177k · Cited by 1,827
Phthalimide conjugation as a strategy for in vivo target protein degradation
Winter, G. E., Buckley, D. L., Paulk, J., Roberts, J. M., Souza, A., Dhe-Paganon, S., & Bradner, J. E. (2015) · Science · doi:10.1126/science.aab1433 · Cited by 1,760
Induced protein degradation: an emerging drug discovery paradigm
Lai, A. C., & Crews, C. M. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.211 · Cited by 1,486
Catalytic in vivo protein knockdown by small-molecule PROTACs
Bondeson, D. P., Mares, A., Smith, I. E. D., Ko, E., Campos, S., Miah, A. H., Mulholland, K. E., Routly, N., Buckley, D. L., Gustafson, J. L., et al. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1858 · Cited by 1,356
Structural basis of PROTAC cooperative recognition for selective protein degradation
Gadd, M. S., Testa, A., Lucas, X., Chan, K.-H., Chen, W., Lamont, D. J., Zengerle, M., & Ciulli, A. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2329 · Cited by 1,242
Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4
Lu, J., Qian, Y., Altieri, M., Dong, H., Wang, J., Raina, K., Hines, J., Winkler, J. D., Crew, A. P., Coleman, K., et al. (2015) · Chemistry & Biology · doi:10.1016/j.chembiol.2015.05.009 · Cited by 1,140
Research works printed but not linked: 1
- Chomez, 2001, Cancer Res., 61, 5544
Cited by
Items 201–300 of 324
Bao, Y., Zhu, Y., Wei, X., Fang, Y., Zhu, J., Gao, F., Dong, G., He, S., & Sheng, C. (2025) · Advanced Science · doi:10.1002/advs.202520975 · Cited by 3
Wen, L., Rao, J., Chen, J., Li, F., Chen, X., Guo, S., Cui, B., 邱财生, & Chen, W. (2026) · Materials Today Bio · doi:10.1016/j.mtbio.2026.102767 · Cited by 4
Diversified design strategies for small-molecule PROTACs: How do we select?
Chen, Q., & Liang, J.-H. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.118593 · Cited by 5
Qian, J., Duan, H., Zheng, Q., Yang, Y., Huang, X., Shi, B., & Zhang, Y. (2026) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2026.115821 · Cited by 3
Discovery of a selective CDK7 PROTAC against acute leukemia with low platelet toxicity
Tu, Y., Cai, X., Tao, Z., Zhang, R., Li, X., Chen, B., Zhang, H., Hu, X., Ke, J., Chen, X., et al. (2026) · Leukemia · doi:10.1038/s41375-026-02925-2 · Cited by 3
Advantages of PROTACs in achieving selective degradation of homologous protein families
Yang, L., Mao, X., Zhang, J., Shu, J., Huang, W., Dong, X., Chen, Y., & Wu, M. (2026) · Beilstein Journal of Organic Chemistry · doi:10.3762/bjoc.22.49 · Cited by 3
Liang, C., Ma, X., Chen, X., Dai, C., Sun, X., Li, J. S., 董如云, Dong, P., & Wang, M. (2026) · JACS Au · doi:10.1021/jacsau.6c00250 · Cited by 3
Ma, T., Luo, T., & Wang, M. (2026) · Cell chemical biology · doi:10.1016/j.chembiol.2026.06.010 · Cited by 3
Cell type–selective targeting by heterobifunctional protein binders via in-cell enrichment
Bulldan, A., Zheng, M., Meyners, C., Purder, P. L., Krieger, J., Dreizler, J. K., Geiger, T. M., Repity, M. L., Lein, M. H., Quist-Løkken, I., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-77460-w · Cited by 3
The Potential of Proteolysis-Targeting Chimeras for Weed Control
León, R. G. (2024) · Outlooks on Pest Management · doi:10.1564/v35_feb_04 · Cited by 3
Jin, P., Hasan, M. M., Pepper, A. G. S., Mitchell, S. A., Rahman, K. M., & Pepper, C. J. (2025) · RSC Medicinal Chemistry · doi:10.1039/d5md00316d · Cited by 2
The rise of new targets in melanoma
Bai, X. L., & Flaherty, K. T. (2025) · British Journal of Dermatology · doi:10.1093/bjd/ljaf251 · Cited by 2
Unraveling the secrets of novel PROTACs to improve degradation efficacy
Huang, J., Yang, X., Huang, Q., Gao, Y., Bandaranayake, P. C. G., Kandegama, W. M. W. W., Ashby, C. R., Dong, Y., Wang, Z., & Hao, G. (2025) · Molecular Diversity · doi:10.1007/s11030-025-11273-9 · Cited by 4
Martínez‐Cartró, M., Serrano‐Morrás, Á., Bertran‐Mostazo, A., Castaño‐Muñiz, R., Scaffidi, S., Ivanova, V., Csorba, N., Simon, J., Ábrányi‐Balogh, P., Li, Y., et al. (2025) · Advanced Science · doi:10.1002/advs.202506068 · Cited by 4
Labhade, S., Bhole, R. P., Karwa, P. N., Kapare, H. S., & Singh, S. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04630-w · Cited by 2
Targeting glycolytic enzymes to combat cancer metastasis: Strategies toward clinical translation
Zhang, D., He, Y., & He, Y. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.117499 · Cited by 2
A potent and selective PROTAC degrader of CDK9 as effective inhibitor of HIV-1 RNA synthesis
Yang, B., Ma, L., Yang, X., Wen, J., Yin, W., Li, S., Ji, Y., Wang, Y., Cen, S., & Li, Y. (2025) · Molecular Diversity · doi:10.1007/s11030-025-11393-2 · Cited by 2
De Novo Design of Hexamer‐Linker Dual‐Action Nano‐PROTAC for Tumor‐Specific Ferroptosis
Zhang, N., Wen, Z., Cai, M., Zhou, K., Li, H., Liu, Y., Wu, S. W., Xia, Y., An, H., & Wang, H. (2025) · Angewandte Chemie · doi:10.1002/ange.202509924 · Cited by 2
Emerging methods to improve PROTAC transport across cell membrane
Veisi, F., & Ataei, F. (2026) · Chemical Engineering Journal · doi:10.1016/j.cej.2026.173175 · Cited by 2
An, X., Xie, J., Wang, W., Long, T., Liang, Q., & Hou, J. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105186 · Cited by 3
Wei, Q., Zhang, J., Chen, J., Cai, X., 周金培, Wang, B., Zhang, H., & Cao, P. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.118667 · Cited by 2
Wang, B., Li, Y., Yao, T., Shen, X., Li, H., Jiang, W., Li, X., & Zhu, Z. (2026) · RSC Medicinal Chemistry · doi:10.1039/d5md00963d · Cited by 3
Harnessing reactive oxygen species for precision medicine: ROS-Activatable PROTACs for lung Cancer
Olazábal-Morán, M., Blázquez-Barbadillo, C., Pérez-Izquierdo, E., Muñoz-Silva, M., & Garrido, A. (2026) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2026.115840 · Cited by 3
PROTACs in cancer therapy: targeted degradation of GPX4, PARP and epigenetic regulators
Periyasamy, S., Jarrett, T., Truong, J., & Skouta, R. (2026) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2026.2636394 · Cited by 2
Pan, X., Jin, H., Song, J., Wang, P., Min, H., Nie, G., & Qi, Y. (2026) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2026.115880 · Cited by 2
Targeted proteoform degradation for precision drug design, delivery, and therapy
Cui, C., Zhang, H., Wang, X., Li, N., & Zhan, X. (2026) · Drug Delivery · doi:10.1080/10717544.2026.2665871 · Cited by 2
Histone Deacetylase Meets Protein Degradation: Accelerating Anticancer Drug Discovery
Wang, J.-J., Gao, Y., Ji, X.-Q., Yin, J.-Y., Zhang, M., Wang, B., Liu, H., Feng, S., Wang, N., Lu, G., et al. (2026) · Medicinal Research Reviews · doi:10.1002/med.70052 · Cited by 2
Wu, J., Wang, L., Jian, S., Ji, R., Zuo, Y., Liu, S., Hu, X., & Hu, H. (2026) · ACS Nano · doi:10.1021/acsnano.6c04279 · Cited by 2
Nanoplatform‐Based Delivery Systems for PROTACs
Che, W., Wang, X., Chen, S., Du, M., Wang, W., Liu, D., Fan, S., Wu, Z., Wu, Y., Dong, Y., et al. (2026) · Drug Development Research · doi:10.1002/ddr.70301 · Cited by 2
Chen, S.-J., Yue, S.-W., Zhang, Y.-P., Liang, H., Wu, H.-X., Chen, X., Zhang, B.-X., & Zhang, W. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02862-7 · Cited by 2
Insight into Structure-Activity Relationship of New Compounds for Breast Cancer Treatment
Li, L., & Zhang, Q. (2023) · Current Topics in Medicinal Chemistry · doi:10.2174/0115680266253686230921054429 · Cited by 2
Design and evaluation of anaplastic lymphoma kinase degraders using a covalent fumarate handle
Yu, N., Lee, J., Park, S., Yun, S. K., Ryu, D. H., Kim, J., Kim, J., & Hwang, J. Y. (2024) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2024.130075 · Cited by 2
Zhou, K. X. T., & Bujold, K. E. (2024) · ACS Chemical Biology · doi:10.1021/acschembio.4c00311 · Cited by 2
Sirtuin 3 as a promising target in disease therapy: Model action and drug discovery
Yu, D. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117929 · Cited by 4
Emerging pharmacology of targeted protein degraders
Barghout, S. H., & Eldeeb, M. A. (2025) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/j.jpet.2025.103694 · Cited by 2
Sun, C., Liu, S., Lau, J. W., Yang, H., Chen, Y., & Xing, B. (2025) · Angewandte Chemie · doi:10.1002/ange.202423057 · Cited by 2
Transcription factor degraders
Wang, M., Wei, Y., & Ma, X. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-21816-3.00006-3 · Cited by 1
Interplay of epigenetics and epistasis drives oral submucous fibrosis
Sharma, M., Shetty, S. S., Alhedyan, F. S., & Radhakrishnan, R. A. (2025) · Discover Applied Sciences · doi:10.1007/s42452-025-07571-4 · Cited by 1
He, S., Huang, W., Zhu, Y., Gao, F., Fang, Y., Zhu, J., Bao, Y., Dong, G., & Sheng, C. (2025) · Angewandte Chemie · doi:10.1002/ange.202511467 · Cited by 1
Design, synthesis, and biological evaluation of death-associated protein kinase 1 PROTACs
Wu, X., Li, R., Tian, W., Yao, J., Chen, D., Lee, T. H., & Liu, Y. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.109044 · Cited by 1
Design of Tissue-Selective PROTACs Through Recruiting E3 Ligase Scaffolding Protein MAGEA11
Jacobsen, I. E., Shi, R., Scholtz, C. R., Pomerantz, W. C. K., & Georg, G. I. (2026) · npj Drug Discovery. · doi:10.1038/s44386-026-00081-2 · Cited by 3
PROTAC-based protein degradation: a window of opportunity for melanoma therapy
Gentile, G., D’Aguanno, S., Martile, M. D., Petricca, A., Valentini, E., Scalera, S., & Bufalo, D. D. (2026) · Journal of Biomedical Science · doi:10.1186/s12929-026-01225-2 · Cited by 2
Research progress of PTP1B inhibitors and degraders
Xu, G., Gao, P., Li, H., Fang, Y., & Yang, Z. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.118770 · Cited by 1
Contemporary Developments in PROTACs for Cancer Management: An In-Depth Review
Rahaman, S. A., Venkateswarlu, G., Patel, S., Mishra, P. S., Kumar, R., & Parvez, N. (2026) · Current Topics in Medicinal Chemistry · doi:10.2174/0115680266384226251013054011 · Cited by 1
Sweileh, M. W. (2026) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-026-06482-0 · Cited by 1
Liu, Z.-Y., & Zhou, X.-J. (2026) · Genes & Diseases · doi:10.1016/j.gendis.2026.102226 · Cited by 1
Gu, J., He, M., Wang, W., Hu, J., Yang, X., Lai, M., Li, S., Duan, X., Luo, Q., & Zhang, G. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105384 · Cited by 1
Maurya, A. K., Padrela, L., Agrawal, A. K., Kumar, A., & Kumar, D. M. (2026) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2026.2697992 · Cited by 2
Lu, X. Y., Qiu, F., Liang, H., Wang, X., Xue, M., Wang, J., Shi, J., Zhang, H., & Wang, B. L. (2026) · Advanced Materials · doi:10.1002/adma.73991 · Cited by 1
Discovery of DCAF16-based PROTACs as SHP2 degraders
Pang, X., Gan, Y., Hu, Q., Zheng, W., Liu, Y., Zhang, K., Yang, Y., Chen, L., & Li, H. (2026) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2026.110372 · Cited by 1
Caged Glycan-Antibody Conjugates for Tumor-Selective Activation of Lysosome-Targeting Chimeras
Chen, M., Li, Y., Wei, X., Fu, Q., He, C., Li, Z., Gu, M., Peng, X., & Shi, P. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c01778 · Cited by 1
Zhang, S., Yao, Z., Zeng, N., Liu, Z., Xia, Q., & Wang, S.-G. (2024) · Exploratory Research and Hypothesis in Medicine · doi:10.14218/erhm.2023.00022 · Cited by 1
PROTACs in the Management of Prostate Cancer
Mandlik, D. S., & Mandlik, S. K. (2024) · Springer eBooks · doi:10.1007/978-981-97-5077-1_11 · Cited by 1
Covalent Bifunctional Molecules (CBMs): Achievements and Challenges
Xin, Y., Chen, F., You, Q., Wang, L., & Zhang, Q. (2025) · Medicinal Research Reviews · doi:10.1002/med.70011 · Cited by 4
BacPROTAC-induced degradation of ClpC1 as a new strategy against drug-resistant mycobacteriaPreprint
Junk, L., Schmiedel, V. M., Guha, S., Greb, P., Fischel, K., Rumpel, K., Kaur, P., Krishnamurthy, R. V., Narayanan, S., Kofink, C. C., et al. (2022) · ChemRxiv · doi:10.26434/chemrxiv-2022-8hnrh · Cited by 1
Bivalent ligands as a new universal chemotype of BCL6 degrader by inducing aggregationPreprint
Hu, R., Hu, X.-T., Yang, Y.-Y., Luo, P., Li, C., Liu, Z., Yu, L., & Wang, N. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.02.25.638777 · Cited by 1
UNC-45A: A potential therapeutic target for malignant tumors
Wang, H., & Sun, F. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e31276
Off‐Target Screening Strategies
Roberts, S., & Lightfoot, H. L. (2024) · Wiley eBooks · doi:10.1002/9781394182862.ch4
Shi, R., Zhang, P., Chen, M., Lü, W., Xu, M., Zeng, H., He, J., Wang, Y., Lin, Y., & Liu, J. (2025) · Medicinal Chemistry Research · doi:10.1007/s00044-025-03434-0
An ultrasonically sensitive small-molecule chimera for sono-controllable proteolysis
Zhang, B., Wang, S., Li, C., Zhou, S., Zhang, Y., Xu, G., & Li, J. (2025) · Chemical Communications · doi:10.1039/d5cc02435h
Meng, Y., Zhang, Y., Yu, W., Xing, D., & Wang, C. (2025) · Materials Today Advances · doi:10.1016/j.mtadv.2025.100606
Progress in the Development of PROTAC Degraders of FLT3
Fan, B., Zhou, L., Xie, Y., Huang, W., & Wang, Z. (2025) · ChemistrySelect · doi:10.1002/slct.202503917
Tissue targeting approaches for drug delivery
Zhang, D., Su, D., Alicea-Salas, J. Y., Zang, R., & Wright, M. R. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29808-0.00049-2
PROTACs as New Tools to Study Platelet Function
Trory, J. S., May, C., & Hers, I. (2025) · Springer eBooks · doi:10.1007/978-3-031-96344-5_27
Li, X., Wang, Y., He, T., Tian, J., Qiao, F., & Li, D. (2025) · Biomaterials Science · doi:10.1039/d5bm01333j
Liu, Y., Wu, J., Chen, D., & Han, L. (2025) · Biochemistry · doi:10.1021/acs.biochem.5c00381
EROS protein: Decoding its pivotal role in redox homeostasis and disease pathogenesis
Liang, S., Zhou, Y., Ren, W., Xu, Y., Tang, M., Su, Y., Li, L., & Gao, M. (2025) · Advances in Redox Research · doi:10.1016/j.arres.2025.100147
Multifaceted roles of HDAC7 in disease and the evolving chemical toolkit for its modulation
Nie, W., Ding, B., Chen, X., Jiang, L., He, Q., Cao, J., & Zhu, C.-L. (2025) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2025.130510
SAG/RBX2/ROC2/RNF7 dual E3 ligase: From target identification, validation to drug discovery
Yu, Q., Zhang, S., Li, Z., Liang, T., & Sun, Y. (2026) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2026.189546
Click Chemistry in the Development of PROTACs
Yang, C., Li, H., Liu, D., Li, Y., & Wang, B. (2026) · Topics in heterocyclic chemistry · doi:10.1007/7081_2025_103
Wang, C., Lin, J., Pei, J., Kang, Z., Liu, Z., Li, J., Cai, G., Zhou, Y., Wang, J., Wang, H., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c03442
Large‐Scale Profiling of Kinase Degradation by Using Norbornene‐Based Hydrophobic Tag (HyT) Strategy
Gu, M., Miao, F., Peng, L., Sun, J., Chen, P., Yang, F., Yan, J., Gao, L., Lu, X., Yao, S. Q., et al. (2026) · Angewandte Chemie · doi:10.1002/ange.2319269
Large‐Scale Profiling of Kinase Degradation by Using Norbornene‐Based Hydrophobic Tag (HyT) Strategy
Gu, M., Miao, F., Peng, L., Sun, J., Chen, P., Yang, F., Yan, J., Gao, L., Lu, X., Yao, S. Q., et al. (2026) · Angewandte Chemie International Edition · doi:10.1002/anie.2319269 · Cited by 1
Ghosh, P., Dhir, R., Sharma, D., & Asati, V. (2026) · Molecular Diversity · doi:10.1007/s11030-026-11567-6 · Cited by 1
Kira, K. (2026) · Folia Pharmacologica Japonica · doi:10.1254/fpj.25095
Design, synthesis, and biological evaluation of ALK5 PROTAC degraders for pulmonary fibrosis
Yue, L., Li, Y., Gan, C., Sun, M., Deng, C., Xue, T., Xie, Y., Liu, H., Liu, Z., & Ye, T. (2026) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2026.109945
Li, S., Tian, Z., Ma, Y., Lin, Y., Liu, H., Yang, J., & Wang, P. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c01039
Li, Z., Han, X., Guo, S., & Du, L. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.119107
Demartino, G. (2026) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2026.113311
Deng, Y., Xu, L., Niu, X., Li, J., Xiong, Y., Zhu, G., Lu, Z., Xu, C., Wang, X., Wang, P., et al. (2026) · Redox Biology · doi:10.1016/j.redox.2026.104296
Two Mechanisms One Molecule: Developing a ‘Truly’ Bifunctional Degrader Targeting Rpn13 and CRBN
Loy, C. A., Vinogradsky, S. E., & Trader, D. J. (2026) · Journal of the American Chemical Society · doi:10.1021/jacs.6c02914 · Cited by 1
Sprayable androgen receptor PROTAC degrader for immunomodulation and accelerated skin regeneration
Jang, S. Y., Park, B., Ko, E., 신동원, Jang, Y., Lee, W. S., Lee, J.-H., Lee, A., Park, J., Lee, S. P., et al. (2026) · Chemical Engineering Journal · doi:10.1016/j.cej.2026.179954
Targeted protein degradation technologies for modulating cell-cell communication
Lu, Y., & Wang, M. (2026) · Scientia Sinica Chimica · doi:10.1360/ssc-2026-0145
Targeting DOT1L Epigenetic Moonlighting in MLL-Rearranged Leukemia
Gupta, D. G., Gupta, M., Othman, A. H., Memon, U. A., Schiltz, G. E., & Abdulkadir, S. A. (2026) · Cells · doi:10.3390/cells15151399
Multidimensional Exploration of Platinum Complexes for Cancer Therapy
Jin, S., & Wang, X. (2026) · Angewandte Chemie · doi:10.1002/ange.6256371
Multidimensional Exploration of Platinum Complexes for Cancer Therapy
Jin, S., & Wang, X. (2026) · Angewandte Chemie International Edition · doi:10.1002/anie.6256371
Development of Oncolytic Virus-Proteolysis-Targeting Chimera Conjugates for Tumor Immunotherapy
Gao, Z., Huang, H., Zhi, Y., Wu, H., Guo, Y., Dong, Y., Du, Y., Ji, Z., Yang, S., Wang, Y., et al. (2026) · ACS Nano · doi:10.1021/acsnano.5c21715
Self-citationDrug resistance in cancer radiotherapy: From mechanisms to overcoming strategies
Chen, Y., Cai, C., Xu, X.-C., Yang, Z., Li, J., Pan, Q., Wang, L., Luo, W., Chen, Z., Zeng, L., et al. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108380
Harnessing the E3 Ligase KLHL12 for Tumor‐Selective Protein Degradation
Xu, S., Zhang, X., Hu, S., Wang, X., Ge, Y., Zhao, Z., Zhu, T., Wang, N., Du, L., You, Q., et al. (2026) · Angewandte Chemie · doi:10.1002/ange.3312795
Harnessing the E3 Ligase KLHL12 for Tumor‐Selective Protein Degradation
Xu, S., Zhang, X., Hu, S., Wang, X., Ge, Y., Zhao, Z., Zhu, T., Wang, N., Du, L., You, Q., et al. (2026) · Angewandte Chemie International Edition · doi:10.1002/anie.3312795
Meng, X., Ma, M., Wang, X., Ma, S., Li, Z., Wu, T., Wang, S., & Qin, C. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.08.020
Wang, A., Sang, Y., Zheng, M., Zhang, D., & Ismail, M. (2026) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2026.101199
Expanding the E3 Ligase Landscape: From Small Molecule to Biological Targeted Protein Degradation
Zhao, X., Liu, Y., & Teng, X. (2026) · Handbook of experimental pharmacology · doi:10.1007/164_2026_842
Hegde, Y., Mehta, R. K., Tan, M., Lawrence, T. S., Bridges, A. J., & Nyati, M. K. (2026) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2026.2736536
Peptide-Based Molecular Glues for Targeted Protein Degradation
Aburayan, W. S., Alradwan, I. A., Alsaffar, B., Alhazzaa, O. A., Almughem, F. A., Alshehri, A. A., Alduhaymi, I. S., Fallatah, M., Alturki, M., Alshaya, H. A., et al. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18101208
Jiang, X., Chen, Y., Dang, Y., Gao, Y., Rong, R., Feng, Y., Zhu, Z., Yu, H., Zhang, W., & Xu, Z. (2026) · Advanced Materials · doi:10.1002/adma.75178
Recent Advances in Nanotechnology for Targeted Protein Degradation
Xu, M., Yang, Y., Chen, J., Wang, X., Wang, S., Ma, F., & Shi, L. (2026) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.6c12624
Targeted protein degradation as next-generation therapeutic modality for childhood cancer
Couwenbergh, S. T., van den Boogaard, M. L., Swaak, S. E. M., Eising, S., & Molenaar, J. J. (2026) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2026.103224
Nagmoti, S., Kadam, E., Sakle, N. S., Kapare, H. S., & Karwa, P. N. (2026) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-026-04970-1
Malik, A., Son, S., Lee, J., & Park, K. S. (2026) · Medicinal Research Reviews · doi:10.1002/med.70110
Metadata
- Authors
- Guenette, R. G., Yang, S. W., Min, J., Pei, B., & Potts, P. R.
- Affiliations
- Amgen (United States) (US)
- Corresponding author
- Potts, Patrick Ryan
- Venue
- Chemical Society Reviews
- Publisher
- Royal Society of Chemistry (RSC)
- Published
- 2022
- Volume
- 51
- Issue
- 14
- Pages
- 5740-5756
- ISSN
- 0306-0012 (ISSN-L)
- 1460-4744
- OpenAlex
- W4280616471
- Cited by
- 324
- References
- 133
- Citations by year
- 2026: 87 · 2025: 110 · 2024: 77 · 2023: 40 · 2022: 10
- FWCI
- 6.20
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Chemical Society Reviews (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Keywords
- PROTACs, targeted protein degradation, tissue selectivity, E3 ubiquitin ligase, bifunctional molecules, linker optimization, undruggable proteins, small molecule drug discovery
- MeSH terms
- Ligands, Ubiquitin-Protein Ligases, Proteolysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.